Welcome to AiCuris : The Powerhouse for Anti-Infectives
AiCuris (from 'Anti-infective Cures') is a pharmaceutical company exclusively focused on the discovery, research and development of novel antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases. AiCuris was founded in 2006 by experts from Bayer's virology and bacteriology research divisions.
With its broad and innovative pipeline of novel anti-infectives, tight focus on specialist markets with high medical need, and a team of internationally regarded scientists and drug developers with exceptional track-records in major pharmaceutical and biotech companies, AiCuris is perfectly positioned to grow and thrive, delivering innovative drugs to the market to help patients with severe, life-threatening infections.
Change at the top of AiCuris
After 9 very successful years establishing and developing Wuppertal-based biotech company AiCuris, Prof. Dr. Helga Rübsamen-Schaeff will transition from her function as CEO to assume the role of Chair of the Board, as of March 1st 2015.
Letermovir: Phase 2 results
Publication in NEJM
Letermovir met the study’s two primary efficacy endpoints in CMV-seropositive allogeneic human blood precursor cell recipients (bone marrow transplant patients). Read Merck's and AiCuris' publication in the New England Journal of Medicine.
Join AiCuris and its quest for novel Anti-Infectives
We offer an exciting and challenging working enviroment in an innovative company with a world-class R&D Portfolio.